What happened with ARTV today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Artiva Biotherapeutics is a clinical-stage drug developer focused on AlloNK for autoimmune diseases, with refractory rheumatoid arthritis as its lead indication. AlloNK uses natural killer (NK) cells grown from donated cord blood. Artiva is testing it alongside antibodies such as rituximab: the antibody binds to targeted B cells, and the NK cells help destroy them. The cells are manufactured in advance and frozen for shipment, rather than made individually for each patient.
Artiva has no approved products and has never earned product-sale revenue. It funds development through capital raising and collaboration arrangements, rather than sales to patients or healthcare providers. Future product sales depend on completing development and obtaining regulatory approval; AlloNK carries most of the company's development focus.
GC Cell supplies key licensed technology and supports research and manufacturing alongside Artiva's own San Diego facility. Artiva's core license excludes Asia, Australia and New Zealand, where GC Cell retains rights. The business therefore depends on both advancing AlloNK and maintaining access to GC Cell's technology and services.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Artiva’s prospects hinge on AlloNK’s autoimmune trial results and on GC Cell, its essential NK-cell technology licensor, research partner and manufacturer.
Nkarta, Inc. directly challenges Artiva’s AlloNK with NKX019, donor-derived NK cells engineered to target CD19 in autoimmune diseases, rather than AlloNK’s antibody-assisted B-cell depletion. Watch NKX019’s autoimmune trial results as a competing test of ready-made NK-cell treatment.
Century Therapeutics, Inc. competes with Artiva’s AlloNK by developing ready-made NK- and T-cell treatments for B-cell-mediated autoimmune diseases. Its CNTY-101 results in the CARAMEL trial are the clearest program to watch for this overlap.
Adicet Bio, Inc. offers a competing route to Artiva’s ready-made NK-cell autoimmune therapy: donor-derived gamma delta T cells engineered for off-the-shelf use. Its lead autoimmune candidate, prula-cel, is the program to watch rather than its cancer pipeline.
Cabaletta Bio, Inc. competes with Artiva’s AlloNK strategy for depleting B cells in autoimmune diseases, using engineered T-cell treatments rather than NK cells.
Kyverna Therapeutics, Inc. competes with Artiva in autoimmune disease by developing T cells engineered to recognize treatment targets—CAR-T therapies—rather than Artiva’s NK-cell approach to eliminating disease-causing B cells.
Fate Therapeutics, Inc.’s ready-made NK- and T-cell programs overlap with Artiva’s HER2-targeted AB-201 cancer candidate, especially its HER2-targeted T-cell candidate FT825 / ONO-8250. Ono pays Fate for research and development, so progress in that program is the relevant competitive signal for AB-201.
Cartesian Therapeutics, Inc. competes with Artiva’s NK-cell autoimmune strategy by modifying a patient’s own T cells to destroy disease-causing cells and giving them in repeated doses. Watch Descartes-08, its BCMA-targeted candidate delivered in six weekly infusions, as an alternative to Artiva’s premanufactured donor-cell approach.
Cullinan Therapeutics, Inc. competes with Artiva’s antibody-assisted AlloNK by using CLN-978 to bring T cells to CD19-bearing B cells for depletion in autoimmune diseases. Watch whether CLN-978 delivers the broader B-cell depletion Cullinan describes as a potential advantage.
Allogene Therapeutics, Inc. competes with Artiva’s donor-derived NK-cell therapies by engineering donor T cells into ready-made treatments for autoimmune diseases and cancer. For this comparison, watch its cell-therapy development rather than revenue, which through December 31, 2025 came exclusively from its licensing agreement with Overland Therapeutics.
CRISPR Therapeutics AG competes with Artiva in autoimmune disease and cancer through T cells engineered to recognize treatment targets, its CAR-T candidates. Those programs, rather than its approved blood-disorder treatment CASGEVY, are the part of its portfolio relevant to Artiva’s competitive position.
Adicet Bio, Inc. earningsACET
Adicet Bio, Inc.’s report will show how its ready-made gamma delta T-cell therapy prula-cel is progressing in autoimmune disease, a competing approach to Artiva’s ready-made NK-cell treatment.
Focus on prula-cel’s autoimmune trials, not Adicet’s cancer programs. Clearer progress would mean another ready-made cell therapy is advancing toward the same patients, sharpening future competition for patients and trial resources; limited progress would make this route a weaker near-term challenge, but would not establish that AlloNK works.
Artiva Biotherapeutics, Inc. earningsThis company
Artiva has no product sales and relies on its funding to advance AlloNK; this report will show whether research spending and cash use remain in line with its plan.
Read research and development spending alongside cash used in operating activities. Higher research spending without a matching acceleration in cash use would suggest Artiva is putting more into development without a faster drain; faster cash use without a corresponding rise in research spending would put its runway under pressure. The question is whether both figures still support management’s estimate that funding lasts into the second quarter of 2027.
